KR102409470B1 - Peg화된 돼지 인터페론 및 그의 사용 방법 - Google Patents

Peg화된 돼지 인터페론 및 그의 사용 방법 Download PDF

Info

Publication number
KR102409470B1
KR102409470B1 KR1020187036853A KR20187036853A KR102409470B1 KR 102409470 B1 KR102409470 B1 KR 102409470B1 KR 1020187036853 A KR1020187036853 A KR 1020187036853A KR 20187036853 A KR20187036853 A KR 20187036853A KR 102409470 B1 KR102409470 B1 KR 102409470B1
Authority
KR
South Korea
Prior art keywords
leu
ala
arg
gln
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187036853A
Other languages
English (en)
Korean (ko)
Other versions
KR20190039889A (ko
Inventor
피터 코너 캐닝
니콜라스 크누센
릴리안 스키드모어
Original Assignee
엘랑코 유에스 인코포레이티드
암브룩스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘랑코 유에스 인코포레이티드, 암브룩스, 인코포레이티드 filed Critical 엘랑코 유에스 인코포레이티드
Priority to KR1020227019809A priority Critical patent/KR102518451B1/ko
Publication of KR20190039889A publication Critical patent/KR20190039889A/ko
Application granted granted Critical
Publication of KR102409470B1 publication Critical patent/KR102409470B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020187036853A 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법 Active KR102409470B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227019809A KR102518451B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352163P 2016-06-20 2016-06-20
US62/352,163 2016-06-20
PCT/US2017/037964 WO2017222940A1 (en) 2016-06-20 2017-06-16 Pegylated porcine interferon and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019809A Division KR102518451B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Publications (2)

Publication Number Publication Date
KR20190039889A KR20190039889A (ko) 2019-04-16
KR102409470B1 true KR102409470B1 (ko) 2022-06-16

Family

ID=59258379

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227019809A Active KR102518451B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법
KR1020187036853A Active KR102409470B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020227019809A Active KR102518451B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Country Status (18)

Country Link
US (2) US10960080B2 (enExample)
EP (1) EP3471755B1 (enExample)
JP (2) JP7093311B2 (enExample)
KR (2) KR102518451B1 (enExample)
CN (2) CN109641034B (enExample)
AU (2) AU2017280958A1 (enExample)
BR (1) BR112018076437A2 (enExample)
CA (1) CA3028683A1 (enExample)
CL (1) CL2018003697A1 (enExample)
DK (1) DK3471755T3 (enExample)
EA (1) EA036509B1 (enExample)
ES (1) ES2793773T3 (enExample)
MX (1) MX391970B (enExample)
NZ (1) NZ749962A (enExample)
PL (1) PL3471755T3 (enExample)
PT (1) PT3471755T (enExample)
WO (1) WO2017222940A1 (enExample)
ZA (1) ZA201808352B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
DK3394033T3 (da) 2015-12-22 2021-01-04 Incyte Corp Heterocykliske forbindelser som immunmodulatorer
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3790877T (lt) 2018-05-11 2023-05-10 Incyte Corporation Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099071A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
CN113845599B (zh) * 2021-11-01 2023-09-19 长春萤火虫生物科技有限公司 一种重组猪干扰素融合蛋白及其应用
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049277A1 (en) 2000-07-19 2003-03-13 Yoshihiro Sokawa Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU
US20070237743A1 (en) 2005-06-20 2007-10-11 Villarete Lorelie H Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
US20080132681A1 (en) 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
CN104262480A (zh) 2014-09-28 2015-01-07 重庆理工大学 重组猪长效-α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
AU691225B2 (en) * 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8106160B2 (en) 2007-10-01 2012-01-31 Pharmaessentia Corp. N-terminal modified interferon-alpha
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049277A1 (en) 2000-07-19 2003-03-13 Yoshihiro Sokawa Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU
US20080132681A1 (en) 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
US20070237743A1 (en) 2005-06-20 2007-10-11 Villarete Lorelie H Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN104262480A (zh) 2014-09-28 2015-01-07 重庆理工大学 重组猪长效-α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F LEFEVRE ET AL, J.INTERFERON RES., Vol.6, no.4(1986.08.01.)

Also Published As

Publication number Publication date
US20210177980A1 (en) 2021-06-17
CN109641034B (zh) 2023-08-15
KR20220086700A (ko) 2022-06-23
KR102518451B1 (ko) 2023-04-04
KR20190039889A (ko) 2019-04-16
CN109641034A (zh) 2019-04-16
US10960080B2 (en) 2021-03-30
CL2018003697A1 (es) 2019-05-10
AU2021229132B2 (en) 2023-04-06
AU2021229132A1 (en) 2021-09-30
NZ749962A (en) 2020-06-26
DK3471755T3 (da) 2020-05-18
JP7441892B2 (ja) 2024-03-01
EP3471755A1 (en) 2019-04-24
EP3471755B1 (en) 2020-04-22
JP2019519553A (ja) 2019-07-11
JP2022137063A (ja) 2022-09-21
JP7093311B2 (ja) 2022-06-29
EA201892671A1 (ru) 2019-05-31
CA3028683A1 (en) 2017-12-28
ZA201808352B (en) 2020-08-26
MX2018016295A (es) 2019-09-16
MX391970B (es) 2025-03-21
WO2017222940A1 (en) 2017-12-28
US20190192673A1 (en) 2019-06-27
AU2017280958A1 (en) 2018-12-20
PT3471755T (pt) 2020-05-22
PL3471755T3 (pl) 2020-10-19
BR112018076437A2 (pt) 2019-10-01
CN117024562A (zh) 2023-11-10
EA036509B1 (ru) 2020-11-18
ES2793773T3 (es) 2020-11-16

Similar Documents

Publication Publication Date Title
KR102409470B1 (ko) Peg화된 돼지 인터페론 및 그의 사용 방법
KR20090089316A (ko) Ｐｅｇ 변형된 엑센딘 또는 엑센딘 유사체 및 조성물 및 이의 용도
US7329646B2 (en) Derivatives of the insulinotropic peptide exendin-4 and methods of production thereof
US11530249B2 (en) Long-acting conjugates of GLP-2 derivatives
KR20150008137A (ko) 지속성 옥신토모둘린 변이체 및 이의 생산 방법
KR20220097921A (ko) 인터루킨-22의 치료 유도체
KR20180014754A (ko) 페길화된 옥신토모둘린 변이체
KR20220125289A (ko) Fgf-21 접합체 제제
JP2025106397A (ja) レナラーゼアゴニスト活性を有する安定なペプチド
WO2005105151A1 (en) Pegylated thymosin 1 derivatives
US20220064248A1 (en) Pharmaceutical composition including insulin and glucagon
US20240052330A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
WO2024241086A1 (en) Pegylated bovine interferon lambda and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200513

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220310

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220610

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220610

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220613

End annual number: 3

Start annual number: 1

PG1601 Publication of registration